Hua’s diabetes therapy may be first to show clinical remission

Data from a small study has shown that Hua’s dorzagliatin may be the first new mechanism to induce clinical remission in a majority of early stage Type II diabetes patients by restoring the glucose-sensing ability of beta cells.

The DREAM trial is an observational study that enrolled 69 Type II diabetes patients who had achieved their target of HbA1c levels below 7% while participating in the Phase III SEED study of GCK activator dorzagliatin from Hua Medicine Ltd. (HKEX:2552). Despite not receiving any therapy during DREAM beyond diet and exercise, 65.2% of the patients maintained clinical remission from Type II diabetes at week 52...